Gamida Cell
Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase
- Form
- 8-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0001213900-22-046082
- Document
- 8-K
- Exhibit 99.1
- Press release, dated August 10, 2022
- Makes a Regulation FD disclosure (7.01)
- Discloses other events (8.01)
Not explained yet; the original is on EDGAR.
Similar companies
Same SIC code (2836) and public float not reported.
- Adaptimmune Therapeutics ADAP
- Adverum Biotechnologies ADVM
- AgomAb Therapeutics AGMB
- Alvotech ALVO
- Argenx ARGX
